CD274 and neoplasm: In this work, the research focus was shifted toward developing imaging agents that could not only be used for imaging PD-L1, but that could be used more specifically as a tool to assess the pharmacodynamic behavior of therapeutic mAbs and determine the accessible PD-L1 target levels within the tumor (198).